$SRI

STONERIDGE INC

No enriched coverage for $SRI in the last 7 days.

No SEC Form 4 filings for $SRI in the last 30 days.

Med

Stoneridge Q1 2026 slides: margins expand despite revenue miss

Stoneridge Inc. (NYSE:SRI) reported mixed Q1 2026 results, missing analyst expectations for EPS and revenue but showcasing significant sequential operational improvements. The company's adjusted gross margin expanded, and its MirrorEye camera system achieved record revenue, leading to reaffirmed full-year guidance with adjusted operating margin improvements. Despite market headwinds and a revenue miss, strategic program wins and a strengthened balance sheet indicate progress.

Stoneridge Reports Fourth Quarter and Full-Year 2025 Results

Stoneridge Inc. announced its fourth quarter and full-year 2025 financial results, reporting fourth-quarter sales of $205.2 million and a net loss of $(76.9) million. Despite challenging macroeconomic conditions, the company outperformed end-markets by 150 basis points, driven by 69% growth in MirrorEye® sales. Stoneridge also provided 2026 midpoint EBITDA guidance of $22.5 million and a 2027 EBITDA target of $44 million, emphasizing a focus on higher-growth businesses following the sale of its Control Devices segment.